Literature DB >> 28042502

Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.

Ya-Wen Ma1, Yi-Zhi Liu1, Jing-Xuan Pan1.   

Abstract

Uveal melanoma (UM) is the most common primary ocular malignancy in adults. Currently, no beneficial systemic therapy is available; therefore, there is an urgent need for effective targeted therapeutic drugs. As verteporfin has shown anti-neoplastic activity in several types of cancers, here we hypothesized and investigated the efficacy of verteporfin against UM cells without light activation. MTS assay, flow cytometry analysis of apoptosis, Western blotting of relevant proteins, transwell migration and invasion assay, melanosphere culture, and measurement of ALDH+ populations, were used to evaluate the effects of verteporfin on UM cells. We found that verteporfin disrupted the interaction between YAP and TEAD4 in UM cells and decreased the expression of YAP targeted downstream genes. Verteporfin treatment decreased the cytoplasmic and nuclear levels of YAP and induced lysosome-dependent degradation of YAP protein. Verteporfin exhibited distinct inhibitory effect on the proliferation of four lines of UM cells (e.g., 92.1, Mel 270, Omm 1 and Omm 2.3), and induced apoptosis through the intrinsic pathway. Additionally, verteporfin suppressed migration and invasion of UM cells, impaired the traits of cancer stem-like cells (e.g., melanosphere formation capacity, and ALDH+ cell population). This study demonstrated the anti-neoplastic activity of verteporfin against UM cells in vitro, providing a rationale for evaluating this agent in clinical investigation.

Entities:  

Keywords:  Apoptosis; YAP; cancer stem-like cells; uveal melanoma; verteporfin

Year:  2016        PMID: 28042502      PMCID: PMC5199756     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  46 in total

1.  Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Authors:  Yanli Jin; Jingfeng Zhou; Fang Xu; Bei Jin; Lijing Cui; Yun Wang; Xin Du; Juan Li; Peng Li; Ruibao Ren; Jingxuan Pan
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

2.  The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis.

Authors:  Ya-Ling Che; Shu-Juan Luo; Gang Li; Min Cheng; Yi-Meng Gao; Xue-Mei Li; Jie-Min Dai; Huan He; Jin Wang; Hui-Juan Peng; Yu Zhang; Wen-Yan Li; Hui Wang; Bin Liu; Hua Linghu
Journal:  Cancer Lett       Date:  2015-01-21       Impact factor: 8.679

3.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

4.  In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid.

Authors:  Margarete K Akens; Lisa Wise-Milestone; Emily Won; Joerg Schwock; Albert J M Yee; Brian C Wilson; Cari M Whyne
Journal:  Photodiagnosis Photodyn Ther       Date:  2014-05-15       Impact factor: 3.631

5.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

6.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Authors:  Xiaodong Feng; Maria Sol Degese; Ramiro Iglesias-Bartolome; Jose P Vaque; Alfredo A Molinolo; Murilo Rodrigues; M Raza Zaidi; Bruce R Ksander; Glenn Merlino; Akrit Sodhi; Qianming Chen; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

Review 7.  GNAQ and GNA11 mutations in uveal melanoma.

Authors:  Alexander N Shoushtari; Richard D Carvajal
Journal:  Melanoma Res       Date:  2014-12       Impact factor: 3.599

8.  Establishment and characterization of an uveal-melanoma cell line.

Authors:  I De Waard-Siebinga; D J Blom; M Griffioen; P I Schrier; E Hoogendoorn; G Beverstock; E H Danen; M J Jager
Journal:  Int J Cancer       Date:  1995-07-17       Impact factor: 7.396

Review 9.  Evidence for the Role of Blue Light in the Development of Uveal Melanoma.

Authors:  Patrick Logan; Miguel Bernabeu; Alberto Ferreira; Miguel N Burnier
Journal:  J Ophthalmol       Date:  2015-05-17       Impact factor: 1.909

10.  The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Authors:  Yingying Shen; Xiaoke Shi; Jingxuan Pan
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

View more
  25 in total

1.  Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy.

Authors:  Yan Baglo; Aaron J Sorrin; Barry J Liang; Huang-Chiao Huang
Journal:  Photochem Photobiol       Date:  2020-02-16       Impact factor: 3.421

2.  In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.

Authors:  Samantha Guillemette; Charlène Rico; Philippe Godin; Derek Boerboom; Marilène Paquet
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-08-18       Impact factor: 2.673

3.  The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Authors:  Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert
Journal:  Mol Cancer Res       Date:  2019-11-15       Impact factor: 5.852

4.  Active epithelial Hippo signaling in idiopathic pulmonary fibrosis.

Authors:  Jason J Gokey; Anusha Sridharan; Yan Xu; Jenna Green; Gianni Carraro; Barry R Stripp; Anne-Karina T Perl; Jeffrey A Whitsett
Journal:  JCI Insight       Date:  2018-03-22

Review 5.  Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy.

Authors:  Simin Zhang; Zhen Yang; Fazhi Qi
Journal:  Mol Biol Rep       Date:  2019-12-14       Impact factor: 2.316

6.  Verteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation.

Authors:  Min Chen; Liang Zhong; Shi-Fei Yao; Yi Zhao; Lu Liu; Lian-Wen Li; Ting Xu; Liu-Gen Gan; Chun-Lan Xiao; Zhi-Ling Shan; Bei-Zhong Liu
Journal:  Int J Med Sci       Date:  2017-09-03       Impact factor: 3.738

7.  Grb2-associated binder 2 expression and its roles in uveal melanoma invasion.

Authors:  Meiling Chen; Yuehua Li; Xiuning Sun; Baogang Zhang; Wei Li; Shuxiao Wang; Xuetao Zhu; Feng Li; Lihong Shi
Journal:  Mol Med Rep       Date:  2017-08-03       Impact factor: 2.952

8.  Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.

Authors:  Liang Dong; Fan Lin; Wanjun Wu; Yuchen Liu; Weiren Huang
Journal:  Int J Med Sci       Date:  2018-04-03       Impact factor: 3.738

9.  Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.

Authors:  Xiangxiang Zhou; Na Chen; Hongzhi Xu; Xiaoming Zhou; Jianhong Wang; Xiaosheng Fang; Ya Zhang; Ying Li; Juan Yang; Xin Wang
Journal:  J Hematol Oncol       Date:  2020-06-16       Impact factor: 17.388

Review 10.  Repurposing of Drugs Targeting YAP-TEAD Functions.

Authors:  Gian Marco Elisi; Matteo Santucci; Domenico D'Arca; Angela Lauriola; Gaetano Marverti; Lorena Losi; Laura Scalvini; Maria Laura Bolognesi; Marco Mor; Maria Paola Costi
Journal:  Cancers (Basel)       Date:  2018-09-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.